[1] |
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894[J]. Ann Surg, 1894, 20(5):497-555.
|
[2] |
Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial [J].Ann Surg, 2016, 264(3):413-420.
|
[3] |
Vijayaraghavan GR, Vedantham S, Kataoka M, et al. The relevance of ultrasound imaging of suspicious axillary lymph nodes and fine-needle aspiration biopsy in the post-ACOSOG Z11 era in early breast cancer[J].Acad Radiol, 2017, 24 (3):308-315.
|
[4] |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial [J].JAMA, 2017, 318(10):918-926.
|
[5] |
Wetzig N, Gill PG, Espinoza D, et al. Sentinel-lymph-node-based management or routine axillary clearance five-year outcomes of the RACS sentinel node biopsy versus axillary clearance (SNAC) 1 trial: assessment and incidence of true lymphedema[J].Ann Surg Oncol, 2017, 24(4):1064-1070.
|
[6] |
张晓东,梁运升.乳腺癌前哨淋巴结检测及其临床意义[J].解放军预防医学杂志,2018, 36(4):477-479.
|
[7] |
Ibis K, Ozkurt S, Kucucuk S, et al. Comparison of pathological prognostic stage and anatomic stage groups according to the updated version of the American Joint Committee on Cancer (AJCC) breast cancer staging 8th edition [J].Med Sci Monit, 2018, 24:3637-3643.
|
[8] |
Tallet A, Lambaudie E, Cohen M, et al. Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy [J]. World J Clin Oncol, 2016, 7(2): 243-252.
|
[9] |
Jagsi R, Chadha M, Moni J, et al. Radiation field design in the ACOSOG Z0011 (Alliance) trial[J]. J Clin Oncol, 2014, 32(32):3600-3606.
|
[10] |
Pepels MJ, de Boer M, Bult P, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells [J].Ann Surg, 2012, 255(1):116-121.
|
[11] |
Francissen CM, Dings PJ, van Dalen T, et al. Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature [J]. Ann Surg Oncol, 2012, 19(13):4140-4149.
|
[12] |
de Boer M, van Deurzen CH, van Dijck JA, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer [J]. N Engl J Med, 2009, 36(1): 653-663.
|
[13] |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel node micrometastases (IBCSG 23-01): a phase 3 randomized controlled trial[J]. Lancet Oncol, 2013, 14(4): 297-305.
|
[14] |
Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer[J].N Engl J Med, 2003, 349(6):546-553.
|
[15] |
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial[J].Ann Surg, 2010, 252(3):426-432.
|
[16] |
Belmonte R, Messaggi-Sartor M, Ferrer M, et al. Prospective study of shoulder strength, shoulder range of motion, and lymphedema in breast cancer patients from pre-surgery to 5 years after ALND or SLNB [J].Support Care Cancer, 2018, 26 (9): 3277-3287.
|
[17] |
Siotos C, Sebai ME, Wan EL, et al. Breast reconstruction and risk of arm lymphedema development: A meta analysis[J].J Plast Reconstr Aesthet Surg, 2018, 71(6):807-818.
|
[18] |
Gratzon A, Schultz J, Secrest K, et al.Clinical and psychosocial outcomes of vascularized lymph node transfer for the treatment of upper extremity lymphedema after breast cancer therapy[J].Ann Surg Oncol, 2017, 24(6):1475-1481.
|
[19] |
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J].Lancet Oncol, 2010, 11(10):927-933.
|
[20] |
Van Zee KJ, Kattan MW. Validating a predictive model for presence of additional disease in the non-sentinel lymph nodes of a woman with sentinel node positive breast cancer [J].Ann Surg Oncol, 2007, 14(8):2177-2178.
|
[21] |
Malter W, Hellmich M, Badian M, et al. Factors predictive of sentinel lymph node involvement in primary breast cancer [J].Anticancer Res, 2018, 38(6):3657-3662.
|
[22] |
Nowikiewicz T, Zegarski W, Pagacz K, et al. The current application of ACOSOG Z0011 trial results: Is further implementation of sentinel lymph node intra-operative histopathological examination mandatory in breast cancer patients-a single-centre analysis [J].Neoplasma, 2018, 65(3):449-454.
|
[23] |
Geertsema D, Gobardhan PD, Madsen EV, et al. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy[J].Ann Surg Oncol, 2010, 17(10):2690-2695.
|
[24] |
Jakub JW, Bryant K, Huebner M, et al. The number of axillary lymph nodes involved with metastatic breast cancer does not affect outcome as long as all disease is confined to the sentinel lymph nodes[J].Ann Surg Oncol, 2011, 18(1):86-93.
|